Awakn Life Sciences Completes Previously Announced Private Placement for Gross Proceeds of $8.3 Million
Retrieved on:
Tuesday, June 8, 2021
Ltd. (the "Company") and Awakn Life Sciences Inc. ("Awakn") are pleased to announce the closing of the previously announced brokered private placement of 3,320,220 subscription receipts (the "Subscription Receipts") in the capital of Awakn at a price of $2.50 per Subscription Receipt (the "Issue Price") for aggregate gross proceeds of $8,300,550 (the "Offering").
Key Points:
- Ltd. (the "Company") and Awakn Life Sciences Inc. ("Awakn") are pleased to announce the closing of the previously announced brokered private placement of 3,320,220 subscription receipts (the "Subscription Receipts") in the capital of Awakn at a price of $2.50 per Subscription Receipt (the "Issue Price") for aggregate gross proceeds of $8,300,550 (the "Offering").
- Lead investors that participated in the offering, include Ambria, Iter Investments, JLS, Negev Capital and Neo Kuma Ventures, among others, settled directly with Awakn.
- The resulting issuer from the Proposed Transaction (the "Resulting Issuer") will carry on the business of Awakn.
- Awakn Life Sciences ( www.awaknlifesciences.com ) is a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat Addiction.